NTRA - Natera wins favorable ruling in CareDx false advertising lawsuit

2023-07-17 17:38:24 ET

Genetic testing company Natera ( NASDAQ: NTRA ) said on Monday that a Delaware court issued a decision in its favor in the false advertising lawsuit brought by rival CareDx ( NASDAQ: CDNA ).

The Austin-based company said that the Delaware court reversed a decision by a jury in March 2022, and ruled CareDx is no longer entitled to any damages.

In March 2022, a Delaware jury decided that Natera owed California-based CareDx $44.9 million in damages .

"Separately, the jury’s March 2022 verdict that CareDx engaged in false advertising against Natera, in violation of the Lanham Act, remains in place," Natera said in a statement .

For further details see: